P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000847280.69256.81 |
| _version_ | 1827336347476557824 |
|---|---|
| author | L. H. Sehn K. Hübel S. Luminari A. Salar B. E. Wahlin A. K. Gopal C. Bonnet S. Paneesha M. Trneny H. Mashegu C. Lihou D. Li C. W. Scholz |
| author_facet | L. H. Sehn K. Hübel S. Luminari A. Salar B. E. Wahlin A. K. Gopal C. Bonnet S. Paneesha M. Trneny H. Mashegu C. Lihou D. Li C. W. Scholz |
| author_sort | L. H. Sehn |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:29:08Z |
| format | Article |
| id | doaj.art-922f3ee2b2714e2c810d8cbdcb20a92d |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:29:08Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-922f3ee2b2714e2c810d8cbdcb20a92d2024-03-02T06:40:53ZengWileyHemaSphere2572-92412022-06-01699399410.1097/01.HS9.0000847280.69256.81202206003-00993P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)L. H. Sehn0K. Hübel1S. Luminari2A. Salar3B. E. Wahlin4A. K. Gopal5C. Bonnet6S. Paneesha7M. Trneny8H. Mashegu9C. Lihou10D. Li11C. W. Scholz121 BC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, Canada2 Department of Internal Medicine I Oncology and Hematology, University Hospital Cologne, Cologne, Germany3 Hematology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy4 Department of Haematology, Hospital del Mar-IMIM, Barcelona, Spain5 Department of Medicine, Unit of Hematology, Karolinska Institute, Stockholm, Sweden6 Division of Medical Oncology, University of Washington Medicine, Seattle, United States of America7 Clinical Hematology, Centre Hospitalier Universitaire, University of Liège, Liège, Belgium8 University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom9 First Department of Medicine, First Faculty of Medicine, Charles University, General Hospital, Prague, Czechia10 Incyte Corporation, Wilmington, United States of America10 Incyte Corporation, Wilmington, United States of America10 Incyte Corporation, Wilmington, United States of America11 Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germanyhttp://journals.lww.com/10.1097/01.HS9.0000847280.69256.81 |
| spellingShingle | L. H. Sehn K. Hübel S. Luminari A. Salar B. E. Wahlin A. K. Gopal C. Bonnet S. Paneesha M. Trneny H. Mashegu C. Lihou D. Li C. W. Scholz P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL) HemaSphere |
| title | P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL) |
| title_full | P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL) |
| title_fullStr | P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL) |
| title_full_unstemmed | P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL) |
| title_short | P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL) |
| title_sort | p1103 inmind a phase 3 study of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab for relapsed refractory follicular lymphoma fl or marginal zone lymphoma mzl |
| url | http://journals.lww.com/10.1097/01.HS9.0000847280.69256.81 |
| work_keys_str_mv | AT lhsehn p1103inmindaphase3studyoftafasitamabpluslenalidomideandrituximabversusplacebopluslenalidomideandrituximabforrelapsedrefractoryfollicularlymphomaflormarginalzonelymphomamzl AT khubel p1103inmindaphase3studyoftafasitamabpluslenalidomideandrituximabversusplacebopluslenalidomideandrituximabforrelapsedrefractoryfollicularlymphomaflormarginalzonelymphomamzl AT sluminari p1103inmindaphase3studyoftafasitamabpluslenalidomideandrituximabversusplacebopluslenalidomideandrituximabforrelapsedrefractoryfollicularlymphomaflormarginalzonelymphomamzl AT asalar p1103inmindaphase3studyoftafasitamabpluslenalidomideandrituximabversusplacebopluslenalidomideandrituximabforrelapsedrefractoryfollicularlymphomaflormarginalzonelymphomamzl AT bewahlin p1103inmindaphase3studyoftafasitamabpluslenalidomideandrituximabversusplacebopluslenalidomideandrituximabforrelapsedrefractoryfollicularlymphomaflormarginalzonelymphomamzl AT akgopal p1103inmindaphase3studyoftafasitamabpluslenalidomideandrituximabversusplacebopluslenalidomideandrituximabforrelapsedrefractoryfollicularlymphomaflormarginalzonelymphomamzl AT cbonnet p1103inmindaphase3studyoftafasitamabpluslenalidomideandrituximabversusplacebopluslenalidomideandrituximabforrelapsedrefractoryfollicularlymphomaflormarginalzonelymphomamzl AT spaneesha p1103inmindaphase3studyoftafasitamabpluslenalidomideandrituximabversusplacebopluslenalidomideandrituximabforrelapsedrefractoryfollicularlymphomaflormarginalzonelymphomamzl AT mtrneny p1103inmindaphase3studyoftafasitamabpluslenalidomideandrituximabversusplacebopluslenalidomideandrituximabforrelapsedrefractoryfollicularlymphomaflormarginalzonelymphomamzl AT hmashegu p1103inmindaphase3studyoftafasitamabpluslenalidomideandrituximabversusplacebopluslenalidomideandrituximabforrelapsedrefractoryfollicularlymphomaflormarginalzonelymphomamzl AT clihou p1103inmindaphase3studyoftafasitamabpluslenalidomideandrituximabversusplacebopluslenalidomideandrituximabforrelapsedrefractoryfollicularlymphomaflormarginalzonelymphomamzl AT dli p1103inmindaphase3studyoftafasitamabpluslenalidomideandrituximabversusplacebopluslenalidomideandrituximabforrelapsedrefractoryfollicularlymphomaflormarginalzonelymphomamzl AT cwscholz p1103inmindaphase3studyoftafasitamabpluslenalidomideandrituximabversusplacebopluslenalidomideandrituximabforrelapsedrefractoryfollicularlymphomaflormarginalzonelymphomamzl |